The contract manufacturing division of Swiss giant Novartis (NOVN: VX) has signed an initial agreement to manufacture macrophage-based therapies for Carisma Therapeutics.
The Pennsylvania, USA-based company is pioneering the development of engineered macrophage-based therapeutics in cancer.
There is a growing body of research indicating that macrophages could be a promising target for cancer immunotherapies, with many such targets and related pharmacological agents having been identified by researchers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze